Avatar Modellers join Global Cancer Network

Vivan Therapeutics, providers of drosophila (fruit fly) ‘avatars’ for cancer research and development, has joined Repositive’s global network of cancer model partners. The London-based company’s proprietary technology enables them to engineer the genetic complexity of a cancer patient's unique tumour network (up to 20 mutations or alterations) into an army of 500,000 fruit flies, which can then be screened for responses to up to 2,000 FDA approved drugs (including non-cancer drugs) and investigational drugs, to identify drug combinations that are efficacious in the individual's personalised

fly population.

Repositive’s Cancer Models Scout subscription service provides tailored model recommendations to researchers based on a search across its network of up to 20,000 preclinical models, providing faster time frames for oncology studies.

 “Vivan Therapeutics offers something different to our customers that we haven’t had in our model network before. With cancer research becoming more and more focused around personalised medicine, we know it is important to keep expanding our offering in this area and partnering with Vivan is allowing us to do so,” said Catherine McDermott, CEO of Repositive.

“Our avatars allow us to do what no other model can - replicate polygenic tumour complexity in a living, biological system for high throughput drug screening. Our library of personalised Drosophila models is ever expanding, and we can also create custom models for biopharma clients. We are excited to become part of the Repositive network to provide our cancer models and services to the global academic and commercial development community.” said Laura Towart, CEO of Vivan Therapeutics.